Electromed, Inc. Q3 FY2026 earnings call

• Core Financial Performance

  • ElectroMed achieved 14 consecutive quarters of year-over-year revenue and profit growth, with total Q3 2026 net revenue of $18.6 million, up 18.4% year-over-year.
  • Operating income grew 76% year-over-year to $3.8 million; diluted earnings per share hit 35 cents, up 67% year-over-year; gross margin expanded to 78.8% from 78.0% year-over-year.
  • The company held $17 million in cash as of quarter-end, with no debt and a strong balance sheet.
  • The board approved a $10 million stock repurchase authorization in Q1, but the company slowed repurchase activity in Q3 to assess macroeconomic market dynamics.

• Strategic Market Opportunity & Clinical Education Campaigns

  • The company's core strategic opportunity is the large underserved bronchiectasis market in the U.S.: ~923,000 diagnosed patients, with only 16% currently prescribed high-frequency chest wall oscillation (HFCWO) therapy, leaving ~800,000 untreated, plus an estimated 4 million additional undiagnosed patients.
  • ElectroMed launched the Triple Down on Bronchiectasis campaign, centered on a three-pronged treatment paradigm: clear airways first with SmartVest, treat infection with antibiotics, and reduce inflammation, to break the cycle of progressive lung damage.
  • The 18-month digital "Clear Airways First" campaign has generated over 2 million impressions and 65,000 visits to educational landing pages. In Q3 alone, the clinical team presented at 4 regional respiratory conferences, hosted 4 peer-to-peer virtual webinars attended by 375+ clinicians, and exhibited at 3 national specialty conferences.
  • A recent published manuscript from NTM Bronchiectasis Research Registry data found 58% of eligible patients are not prescribed HFCWO despite meeting clinical criteria; the company's Sip On This campaign targets high-diagnosis physicians not currently prescribing HFCWO to close this care gap.

• Operational & Product Innovation

  • The company launched a smart order electronic prescribing solution that already meets CMS requirements to phase out faxed orders by 2028. In Q3, over 40% of orders were processed through this solution, cutting average shipping time by five days compared to faxed orders, improving patient access and clinic workflow.
  • Payer coverage expansion has reached 86% of eligible U.S. covered lives under contract; new covered lives added in the past 18 months have generated over 50 additional previously unrecoverable referrals.
  • The company's manufacturing optimization initiative, launched in 2025, is complete. Facility restructuring has added production capacity for future growth, all products are assembled domestically in the U.S., and the company has maintained strong on-time delivery and gross margins amid global uncertainty.

• Sales Team Expansion

  • Q3 ended with 58 direct sales reps, flat from Q2, but the company has since added 4 reps to reach 62 total filled territories, exceeding the original fiscal 2026 target of 61 territories.

1. Direct Home Care: Revenue of $16.7 million, representing 18.6% year-over-year growth, accounting for 89.8% of total Q3 2026 net revenue. Annualized revenue per weighted average direct sales representative hit $1,168,000, exceeding the $1 million to $1.1 million target range for the second consecutive quarter.
2. Hospital: Revenue of $1.0 million, growing 42.5% year-over-year, accounting for 5.4% of total net revenue, rebounding from a slow Q2 performance.
3. Home Care Distributor: Revenue of $0.7 million, growing 2.7% year-over-year, accounting for 3.8% of total net revenue.
4. Other: Revenue of $0.1 million, declining 40.7% year-over-year, accounting for 0.5% of total net revenue.

• Management does not expect the Q3 2026 growth rates (18.4% revenue growth, 76% operating income growth) to become the new quarterly normal.
• The company reaffirms confidence in delivering sustained double-digit year-over-year revenue growth with expanding operating leverage for the remainder of fiscal 2026 and beyond.
• For the next fiscal year, management plans to add 4 to 5 additional direct sales territories to expand market coverage.

• Forward-looking statements about future performance and market opportunity are subject to inherent risks and uncertainties that could cause actual results to differ materially from projections, and the company does not undertake to update forward-looking statements.
• Natural sales team churn creates uncertainty around headcount planning and territory filling, though the company proactively works to maintain fully staffed territories.
• Ongoing macroeconomic market uncertainty led the company to slow share repurchase activity in the quarter, reflecting general macro risk exposure.

Q: Given that strong revenue per rep has outperformed targets despite recent headcount additions, are you adding new territories or splitting existing ones, and what is your planned headcount upper bound for coming periods? / A: Strong recent performance stems from existing productive reps plus favorable insurance mix tailwinds. The company already exceeded its original fiscal 2026 target of 61 filled territories, reaching 62. For the next fiscal year, it plans to add 4 to 5 additional new reps and territories to expand market coverage. It is already executing on this expansion as Q4 concludes.

Q: Do you still see the Brinsupri bronchiectasis drug as a net positive for SmartVest? / A: Yes, Brinsupri is a net positive. Brinsupri addresses inflammation, which is only one part of the chronic disease treatment cycle, while SmartVest addresses the core need of clearing built-up mucus that drives recurring infections. The drug has raised overall patient and provider awareness of bronchiectasis, which has benefited all market participants. Preliminary CHEST treatment guidelines also confirm airway clearance (including SmartVest) as a required part of the care continuum, which further validates the company's position. Brinsupri is an adjunct treatment, not a replacement for HFCWO therapy.

Q: What is the typical ramp-up timeline for new sales reps, and are new positions filling turnover or adding new territories? / A: The typical ramp-up to full productivity for a new rep is 4 to 6 months, and the company is working to shorten this timeline. Most of the 62 current reps were for planned fiscal 2026 territory expansions, though a small number filled spots opened by recent retirements. Some level of sales team churn is unavoidable, but the company prioritizes keeping all territories fully staffed, as this is still primarily a direct clinical sales model that requires in-person engagement with pulmonologists.

Q: Can you quantify how many clinicians who attend your educational events convert to new SmartVest prescribers? / A: The company tracks attendee behavior, but most current event activity is focused on building disease and treatment awareness, not immediate conversion. Many clinicians attending are still being introduced to bronchiectasis treatment guidelines and HFCWO options, so conversion will happen gradually over time. The company will continue its educational outreach at upcoming major conferences like ATS to build long-term prescribing momentum.